Cargando…

The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease

BACKGROUND: This study was conducted to evaluate the effects of probiotic supplementation on metabolic profiles in diabetic patients with coronary heart disease (CHD). METHODS: This randomized, double-blind, placebo-controlled trial was performed among 60 diabetic patients with CHD, aged 40–85 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Raygan, Fariba, Rezavandi, Zohreh, Bahmani, Fereshteh, Ostadmohammadi, Vahidreza, Mansournia, Mohammad Ali, Tajabadi-Ebrahimi, Maryam, Borzabadi, Shokoofeh, Asemi, Zatollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008939/
https://www.ncbi.nlm.nih.gov/pubmed/29946368
http://dx.doi.org/10.1186/s13098-018-0353-2
_version_ 1783333282560081920
author Raygan, Fariba
Rezavandi, Zohreh
Bahmani, Fereshteh
Ostadmohammadi, Vahidreza
Mansournia, Mohammad Ali
Tajabadi-Ebrahimi, Maryam
Borzabadi, Shokoofeh
Asemi, Zatollah
author_facet Raygan, Fariba
Rezavandi, Zohreh
Bahmani, Fereshteh
Ostadmohammadi, Vahidreza
Mansournia, Mohammad Ali
Tajabadi-Ebrahimi, Maryam
Borzabadi, Shokoofeh
Asemi, Zatollah
author_sort Raygan, Fariba
collection PubMed
description BACKGROUND: This study was conducted to evaluate the effects of probiotic supplementation on metabolic profiles in diabetic patients with coronary heart disease (CHD). METHODS: This randomized, double-blind, placebo-controlled trial was performed among 60 diabetic patients with CHD, aged 40–85 years at a cardiology clinic in Kashan, Iran, from October 2017 through January 2018. Patients were randomly divided into two groups to take either probiotic supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at the beginning of the study and after the 12-week intervention to determine related markers. RESULTS: After 12-week intervention, probiotic supplementation significantly decreased fasting plasma glucose (β − 20.02 mg/dL; 95% CI − 33.86, − 6.17; P = 0.005), insulin (β − 2.09 µIU/mL; 95% CI − 3.77, − 0.41; P = 0.01), insulin resistance (β − 0.50; 95% CI − 0.96, − 0.03; P = 0.03) and total-/HDL-cholesterol ratio (β − 0.27; 95% CI − 0.52, − 0.03; P = 0.02), and significantly increased insulin sensitivity (β 0.008; 95% CI 0.001, 0.01; P = 0.02) and HDL-cholesterol levels (β 2.52 mg/dL; 95% CI 0.04, 5.00; P = 0.04) compared with the placebo. Moreover, probiotic supplementation led to a significant reduction in serum high sensitivity C-reactive protein (β − 0.88 mg/L; 95% CI − 1.39, − 0.38; P = 0.001), and a significant elevation in total antioxidant capacity (β 108.44 mmol/L; 95% CI 47.61, 169.27; P = 0.001) and total glutathione levels (β 45.15 µmol/L; 95% CI 5.82, 84.47; P = 0.02) compared with the placebo. Probiotic supplementation did not affect other metabolic profiles. CONCLUSIONS: Overall, we found that probiotic supplementation for 12 weeks had beneficial effects on glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, biomarkers of inflammation and oxidative stress in diabetic patients with CHD. Trial registration Clinical trial registration number http://www.irct.ir: IRCT2017082733941N5
format Online
Article
Text
id pubmed-6008939
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60089392018-06-26 The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease Raygan, Fariba Rezavandi, Zohreh Bahmani, Fereshteh Ostadmohammadi, Vahidreza Mansournia, Mohammad Ali Tajabadi-Ebrahimi, Maryam Borzabadi, Shokoofeh Asemi, Zatollah Diabetol Metab Syndr Research BACKGROUND: This study was conducted to evaluate the effects of probiotic supplementation on metabolic profiles in diabetic patients with coronary heart disease (CHD). METHODS: This randomized, double-blind, placebo-controlled trial was performed among 60 diabetic patients with CHD, aged 40–85 years at a cardiology clinic in Kashan, Iran, from October 2017 through January 2018. Patients were randomly divided into two groups to take either probiotic supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at the beginning of the study and after the 12-week intervention to determine related markers. RESULTS: After 12-week intervention, probiotic supplementation significantly decreased fasting plasma glucose (β − 20.02 mg/dL; 95% CI − 33.86, − 6.17; P = 0.005), insulin (β − 2.09 µIU/mL; 95% CI − 3.77, − 0.41; P = 0.01), insulin resistance (β − 0.50; 95% CI − 0.96, − 0.03; P = 0.03) and total-/HDL-cholesterol ratio (β − 0.27; 95% CI − 0.52, − 0.03; P = 0.02), and significantly increased insulin sensitivity (β 0.008; 95% CI 0.001, 0.01; P = 0.02) and HDL-cholesterol levels (β 2.52 mg/dL; 95% CI 0.04, 5.00; P = 0.04) compared with the placebo. Moreover, probiotic supplementation led to a significant reduction in serum high sensitivity C-reactive protein (β − 0.88 mg/L; 95% CI − 1.39, − 0.38; P = 0.001), and a significant elevation in total antioxidant capacity (β 108.44 mmol/L; 95% CI 47.61, 169.27; P = 0.001) and total glutathione levels (β 45.15 µmol/L; 95% CI 5.82, 84.47; P = 0.02) compared with the placebo. Probiotic supplementation did not affect other metabolic profiles. CONCLUSIONS: Overall, we found that probiotic supplementation for 12 weeks had beneficial effects on glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, biomarkers of inflammation and oxidative stress in diabetic patients with CHD. Trial registration Clinical trial registration number http://www.irct.ir: IRCT2017082733941N5 BioMed Central 2018-06-19 /pmc/articles/PMC6008939/ /pubmed/29946368 http://dx.doi.org/10.1186/s13098-018-0353-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Raygan, Fariba
Rezavandi, Zohreh
Bahmani, Fereshteh
Ostadmohammadi, Vahidreza
Mansournia, Mohammad Ali
Tajabadi-Ebrahimi, Maryam
Borzabadi, Shokoofeh
Asemi, Zatollah
The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
title The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
title_full The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
title_fullStr The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
title_full_unstemmed The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
title_short The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
title_sort effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008939/
https://www.ncbi.nlm.nih.gov/pubmed/29946368
http://dx.doi.org/10.1186/s13098-018-0353-2
work_keys_str_mv AT rayganfariba theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT rezavandizohreh theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT bahmanifereshteh theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT ostadmohammadivahidreza theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT mansourniamohammadali theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT tajabadiebrahimimaryam theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT borzabadishokoofeh theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT asemizatollah theeffectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT rayganfariba effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT rezavandizohreh effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT bahmanifereshteh effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT ostadmohammadivahidreza effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT mansourniamohammadali effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT tajabadiebrahimimaryam effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT borzabadishokoofeh effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease
AT asemizatollah effectsofprobioticsupplementationonmetabolicstatusintype2diabeticpatientswithcoronaryheartdisease